Search results for "Radical surgery"

showing 10 items of 52 documents

Could lymphadenectomy be avoided in locally advanced cervical cancer patients administered preoperative chemoradiation? A large-scale retrospective s…

2017

Abstract Introduction To identify a subset of cervical cancer (CC) patients administered chemoradiation (CT/RT) plus radical surgery (RS), who can be spared lymphadenectomy, and complications. Patients and methods 430 Stage IB2-IIB patients without LN involvement at imaging were accrued (March 1996–December 2015) at Gynecologic Oncology Unit of the Catholic University of Rome/Campobasso. CT/RT consisted of pelvic irradiation plus cisplatin based chemotherapy. Objective response was evaluated according to RECIST criteria; radical hysterectomy and pelvic ± aortic lymphadenectomy was attempted in patients achieving response or stable disease. Surgical morbidity was classified according to the …

0301 basic medicineComplicationsmedicine.medical_treatmentRadical surgeryUterine Cervical Neoplasms0302 clinical medicineCervical cancer Chemoradiation Aged 80 and over Antineoplastic Agents Cisplatin Combined Modality Therapy Female Humans Hysterectomy Middle Aged Neoplasm Staging Retrospective Studies Treatment Outcome Uterine Cervical Neoplasms Chemoradiotherapy Lymph Node Excision Lymphadenectomy Radical surgery80 and overMedicineStage (cooking)Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIAAged 80 and overCervical cancerChemoradiotherapyGeneral MedicineMiddle AgedCombined Modality TherapyLymphovascularTreatment Outcomemedicine.anatomical_structureChemoradiationOncologyCervical cancer; Chemoradiation; Complications; Lymphadenectomy; Radical surgery; Adult; Aged; Aged 80 and over; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Female; Humans; Hysterectomy; Middle Aged; Neoplasm Staging; Retrospective Studies; Treatment Outcome; Uterine Cervical Neoplasms; Chemoradiotherapy; Lymph Node Excision; Surgery; Oncology030220 oncology & carcinogenesisFemaleAdultmedicine.medical_specialtyAntineoplastic AgentsGynecologic oncologyHysterectomy03 medical and health sciencesHumansRadical surgeryRadical HysterectomyCervixAgedNeoplasm StagingRetrospective Studiesbusiness.industryLymphadenectomymedicine.diseaseSurgery030104 developmental biologyCervical cancerLymph Node ExcisionSurgeryLymphadenectomyCervical cancer; Chemoradiation; Complications; Lymphadenectomy; Radical surgery; Adult; Aged; Aged 80 and over; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Female; Humans; Hysterectomy; Middle Aged; Neoplasm Staging; Retrospective Studies; Treatment Outcome; Uterine Cervical Neoplasms; Chemoradiotherapy; Lymph Node ExcisionCisplatinbusinessEuropean Journal of Surgical Oncology
researchProduct

Fast-Growing Alveolar Echinococcosis Following Lung Transplantation

2020

International audience; Alveolar echinococcosis is a rare but life-threatening infection caused by the parasiteEchinococcus multilocularis. Its natural history is characterized by a slow parasitic growth over several years. Increased incidence and shorter development delay have been reported in immune-compromised patients. We report the reactivation of aborted lesions within 12 months of lung transplantation leading to a fast-growing aggressive hepatic lesion. Timely identification of alveolar echninococcosis allowed prompt albendazole treatment and radical surgery leading to a favorable outcome 42 months after transplantation. However, close clinical, serological and radiological monitorin…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtymedicine.medical_treatment030231 tropical medicinelcsh:MedicineCase ReportEchinococcus multilocularisliverAlbendazole03 medical and health sciences0302 clinical medicinemedicinelung transplantationImmunology and AllergyLung transplantationRadical surgeryMolecular Biology<i>Echinococcus multilocularis</i>immunosuppressionGeneral Immunology and Microbiologybiologybusiness.industryIncidence (epidemiology)lcsh:RImmunosuppression030108 mycology & parasitologybiology.organism_classification3. Good healthSurgeryNatural historyTransplantationInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyparasiteEchinococcus multilocularisbusinessmedicine.drug
researchProduct

M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients

2021

Objective. Despite radical surgery and chemotherapy, most patients with ovarian cancer die due to disease progression. M-Trap is an implantable medical device designed to capture peritoneal disseminated tumor cells with the aim to focalize the disease. This trial analyzed the safety and performance of the device. Methods. This first-in-human prospective, multi-center, non-blinded, single-arm study enrolled 23 women with high-grade serous advanced ovarian cancer. After primary or interval debulking surgery, 3 M-Trap devices were placed in the peritoneum of the abdominal cavity. 18-months post-implantation or at disease progression, devices were initially removed by laparoscopy. The primary s…

0301 basic medicineOncologyAdultmedicine.medical_specialtymedicine.medical_treatmentPerformanceDiseaseCarcinoma Ovarian Epithelial03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansCytoreductive surgeryProspective StudiesRadical surgeryNeoplasm MetastasisAdverse effectLaparoscopyPeritoneal NeoplasmsAgedOvarian NeoplasmsChemotherapymedicine.diagnostic_testbusiness.industryM-Trap deviceObstetrics and GynecologyCytoreduction Surgical ProceduresMiddle AgedDebulkingmedicine.diseaseSerous fluid030104 developmental biologyTreatment OutcomeOncologySpain030220 oncology & carcinogenesisAdvanced ovarian cancerFemaleNeoplasm Recurrence LocalRecurrent ovarian cancerSafetyOvarian cancerbusinessPeritoneal carcinomatosis
researchProduct

Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement

2019

AbstractBackgroundNeoadjuvant treatment is increasingly one of the preferred therapeutic options for early breast cancer and may have some unique outcomes, such as identifying predictive and prognostic factors of response or increasing the knowledge of individual tumor biology.DesignA panel of experts from different specialties reviewed published clinical studies on the neoadjuvant management of breast cancer. Recommendations were made that emphasized the clinical multidisciplinary management and the investigational leverage in early breast cancer.ResultsNeoadjuvant therapy has equivalent efficacy to adjuvant therapy, and it has some additional benefits that include increasing breast conser…

0301 basic medicineOncologyPosition statementCancer Researchmedicine.medical_specialtymedicine.medical_treatmentBreast Neoplasms03 medical and health sciences0302 clinical medicineBreast cancerInternal medicineBreast CancermedicineAdjuvant therapyHumansRadical surgeryskin and connective tissue diseasesNeoadjuvant therapyEarly breast cancerChemotherapybusiness.industrymedicine.diseaseNeoadjuvant Therapy030104 developmental biologyOncology030220 oncology & carcinogenesisHormonal therapyFemalebusinessThe Oncologist
researchProduct

Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients

2017

Background: Results from the BEVA2007 trial, suggest that the metronomic chemotherapy regimen with dose-fractioned cisplatin and oral etoposide (mPE) +/− bevacizumab, a monoclonal antibody to the vascular endothelial growth factor (VEGF), shows anti-angiogenic and immunological effects and is a safe and active treatment for metastatic non-small cell lung cancer (mNSCLC) patients. We carried out a retrospective analysis aimed to evaluate the antitumor effects of this treatment in a subset of patients with squamous histology. Methods: Retrospective analysis was carried out in a subset of 31 patients with squamous histology enrolled in the study between September 2007 and September 2015. All o…

0301 basic medicineOncologyPulmonary and Respiratory Medicinemedicine.medical_specialtyPathologyBevacizumabmedicine.medical_treatmentSquamous-NSCLC (sqNSCLC)03 medical and health sciences0302 clinical medicineInternal medicinemedicineProgression-free survivalRadical surgeryEtoposideEtoposideChemotherapybusiness.industryMetronomic chemotherapyCancermedicine.diseaseMetronomic ChemotherapyBevacizumabRegimen030104 developmental biology030220 oncology & carcinogenesisOriginal ArticleCisplatinbusinessBevacizumab; Cisplatin; Etoposide; Metronomic chemotherapy; Squamous-NSCLC (sqNSCLC); Pulmonary and Respiratory Medicinemedicine.drug
researchProduct

Validity of Laparoscopic Staging to Avoid Adjuvant Chemoradiation following Radical Surgery in Patients with Early Cervical Cancer

2012

&lt;b&gt;&lt;i&gt;Purpose:&lt;/i&gt;&lt;/b&gt; To determine the rate of unavoidable adjuvant chemoradiation (RCTX) due to histologic results after radical surgery in patients with early cervical cancer. &lt;b&gt;&lt;i&gt;Patients and Methods:&lt;/i&gt;&lt;/b&gt; Between May 2004 and July 2011, 448 consecutive patients diagnosed with invasive cervical cancer stage IA1 L1 to IIA underwent laparoscopic staging at the Department of Gynecology and Gynecologic Oncology at Charité Berlin. Only in patients without lymph node metastases (n = 394) on frozen section, radical operation was continued either by laparoscopic radical hysterectomy (n = 228) or by radical vaginal trachelectomy (n = 166). The…

AdultCancer Researchmedicine.medical_specialtyAdolescentmedicine.medical_treatmentUterine Cervical NeoplasmsRadical vaginal trachelectomyAdjuvant chemoradiationHysterectomyYoung AdultRisk FactorsEarly cervical cancermedicineHumansRadical hysterectomyProspective StudiesRadical HysterectomyRadical surgeryLaparoscopyProspective cohort studyAgedNeoplasm StagingAged 80 and overCervical cancerHysterectomymedicine.diagnostic_testbusiness.industryGeneral surgeryChemoradiotherapy AdjuvantGeneral MedicineMiddle Agedmedicine.diseaseSettore MED/40 - Ginecologia E OstetriciaSurgeryClinical trialOncologyLymphatic MetastasisAdjuvant chemoradiation; Early cervical cancer; Radical hysterectomyVaginaLymph Node ExcisionFemaleLaparoscopyRisk factorbusinessChemoradiotherapy
researchProduct

Psychosocial adjustment in patients surgically treated for laryngeal cancer.

2003

Abstract Objective To assess the psychosocial adjustment in 62 patients surgically treated for cancer of the head and neck. Study design and setting Forty-one patients were grouped as having had radical surgery (total laryngectomy) and 21 as having had functional surgery (horizontal supraglottic laryngectomy or partial vertical surgery). The Psychosocial Adjustment to Illness Scale-Self Report (PAIS-SR) was used for the evaluation. Results No significant differences were found between groups when global adjustment or domain adjustment was compared. Patients did not consider the permanent stoma and voice loss to be the most important determinant of quality of life. Work and family relationsh…

AdultEmploymentMalemedicine.medical_specialtymedicine.medical_treatmentLaryngectomyStomaQuality of lifeAdaptation PsychologicalmedicineHumansPhonationRadical surgeryLaryngeal NeoplasmsAgedAged 80 and overRehabilitationbusiness.industryCancerSocial SupportMiddle Agedmedicine.diseaseLaryngectomySpeech AlaryngealOtorhinolaryngologyPhysical therapyQuality of LifeSurgeryFemaleFamily RelationsbusinessPsychosocialSocial AdjustmentOtolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
researchProduct

Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer

2011

BACKGROUND: Preoperative chemoradiation is becoming the standard treatment for patients with locally advanced rectal cancer. However, since the introduction of total mesorectal excision (TME), local recurrence rates have been reduced significantly, and some patients can be spared from potentially toxic over treatment. The current study was designed to assess the factors that predict recurrence in an institutional series of patients with rectal cancer who had clinical T2 lymph node-positive (cT2N+) tumors or cT3N0/N+ tumors and underwent radical surgery without receiving preoperative chemoradiation. METHODS: Between November 1997 and November 2008, the authors' multidisciplinary group preope…

AdultMaleCancer Researchmedicine.medical_specialtyColorectal cancermedicine.medical_treatmentAdenocarcinomaDisease-Free SurvivalmedicineHumansRadical surgerySurvival rateAgedNeoplasm StagingMesorectalAged 80 and overRectal Neoplasmsbusiness.industryStandard treatmentCancerMiddle Agedmedicine.diseaseCombined Modality TherapyTotal mesorectal excisionNeoadjuvant TherapySurgerySurvival RateRadiation therapyTreatment OutcomeOncologyLymphatic MetastasisFemaleNeoplasm Recurrence LocalbusinessCancer
researchProduct

Radiation response non-invasively imaged by [18F]FDG-PET predicts local tumor control and survival in advanced oral squamous cell carcinoma

2003

It is a major challenge to preoperatively identify patients who will profit from surgery of advanced oral cancer. In multimodality therapy, response to neoadjuvant radiation correlates to treatment success. Hence, for preoperative decisions, assessment of treatment response is required. Therefore, we analysed the prognostic significance of glucose metabolism after preoperative radiotherapy. [(18)F]FDG-PET investigations were performed for re-staging 35 patients after neoadjuvant radiotherapy (36Gy) immediately prior to tumor resection. Emission and transmission measurements were obtained and SUV's were calculated for the sites of maximum [(18)F]FDG-uptake. Subpopulations of "low" (SUV4) and…

AdultMaleCancer Researchmedicine.medical_treatmentStandardized uptake valuePremisesFluorodeoxyglucose F18Odds RatiomedicineHumansRadical surgerySurvival rateSurvival analysisNeoadjuvant therapyAgedAged 80 and overAnalysis of Variancebusiness.industryMiddle AgedPrognosisNeoadjuvant TherapySurvival RateRadiation therapyTreatment OutcomeOncologyEpidermoid carcinomaMultivariate AnalysisCarcinoma Squamous CellFemaleMouth NeoplasmsRadiotherapy AdjuvantRadiopharmaceuticalsOral SurgeryNuclear medicinebusinessFollow-Up StudiesTomography Emission-ComputedOral Oncology
researchProduct

Malignant peripheral neuroectodermal tumors in urology.

1995

During the past few years, a new tumor type has emerged in the pediatric and adolescent group of cancer patients, which has been designated malignant peripheral neuroectodermal tumor (MPNT). This tumor has some clinical and pathological signs in common with either soft-tissue sarcomas or classic Ewing's sarcoma, but is defined as a distinct entity because of its immunohistological characteristics. The tumor expresses neuronal markers, but the pattern varies: chromogranin, neuron-specific enolase, synaptophysin, protein S-100 and others. MPNT can occur in the urogenital region. The differential diagnosis on clinical grounds must include Ewing's and soft tissue sarcomas, and also Wilms' tumor…

AdultMalePathologymedicine.medical_specialtyUrologic Neoplasmsbusiness.industryUrologySoft tissue sarcomamedicine.medical_treatmentCancerCombination chemotherapymedicine.diseaseCombined Modality TherapyRadiation therapyFatal OutcomemedicineHumansFemaleSarcomaNeuroectodermal Tumors Primitive PeripheralDifferential diagnosisRadical surgeryNeuroectodermal tumorbusinessChildWorld journal of urology
researchProduct